2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106869A
    SM 10888 129297-21-8 98%
    SM 10888 is a selective and orally active cholinesterase (ChE) inhibitor. SM 10888 can increase brain acetylcholine release. SM 10888 can be used for the research of neurological disease, such as Alzheimer's disease.
    SM 10888
  • HY-106874A
    Delequamine hydrochloride 119942-75-5 98%
    Delequamine (RS-15385-197) hydrochloride is an orally active and selective α2-adrenergic receptor antagonist with a pKi of 9.5 for α2-adrenoceptors in rat cortex. Delequamine hydrochloride shows >1000 fold selectivity against 5-HT1A receptors and α1-adrenoceptors. Delequamine hydrochloride can be used for the study of erectile dysfunction.
    Delequamine hydrochloride
  • HY-106874B
    rel-Delequamine 119813-87-5 98%
    rel-Delequamine (rel-RS-15385-197) is an orally active, brain-penetrant, potent and selective M2-adrenoceptor antagonist and α2-adrenoceptor antagonist. rel-Delequamine has a pKi of 9.45 for α2-adrenoceptors in the rat cortex. rel-Delequamine augments K+-evoked release of noradrenaline with an EC50 of 1 nM.
    rel-Delequamine
  • HY-106888A
    CS-722 144886-17-9 98%
    CS-722 is a centrally acting muscle relaxant, and has a muscle relaxant activity and depressant effectson the spinal reflex[1]. CS-722 inhibits spontaneous inhibitory postsynaptic currents and excitatory postsynaptic currents in hippocampal cultures probably by an inhibition of both sodium and calcium currents.
    CS-722
  • HY-106889A
    Zelandopam anhydrous 138086-00-7 98%
    Zelandopam (YM435) anhydrous is an orally active and selective agonist of the dopamine D1 receptor. Zelandopam anhydrous possesses potent renal vasodilatory properties and can effectively alleviate Cisplatin (HY-17394)-induced acute renal failure.
    Zelandopam anhydrous
  • HY-106901B
    Asoxime dimesylate 144252-71-1 98%
    Asoxime dimesylate (HI-6 dimesylate) is an orally active thiosemicarbazone-based antidote. Asoxime dimesylate is a reversible inhibitor of AChE, and its core mechanism of action is to re-activate AChE inhibited by nerve toxins, thereby restoring the cholinergic nerve function. Asoxime dimesylate significantly restores the function of poisoned muscles without reactivating AChE. Asoxime dimesylate is an antagonist of acetylcholine receptors (AChRs), including nicotinic receptor and α7 nAChR. Asoxime dimesylate can serve as an effective immunomodulator, improving the immune effect of the nervous system.
    Asoxime dimesylate
  • HY-106933A
    Dabelotine methanesulfonate 153049-48-0 98%
    Dabelotine (methanesulfonate) is a cognitive enhancer. Dabelotine (methanesulfonate) can be used for Alzheimer disease (AD) research.
    Dabelotine methanesulfonate
  • HY-106935A
    CGP 29030A 113240-27-0 98%
    CGP 29030A is an orally effective and specific analgesic agent. CGP 29030A inhibits nociceptive spinal cord neurons without affecting normal sensory functions. CGP 29030A also inhibits gamma motor neurons, which may be beneficial for studying pain disorders that occur concurrently due to increased motor activity (such as cramp, spasm).
    CGP 29030A
  • HY-106956A
    Lubazodone hydrochloride 161178-10-5 98%
    Lubazodone hydrochloride is a selective serotonin reuptake inhibitor and can be used for study of depression.
    Lubazodone hydrochloride
  • HY-106969A
    ZD 9379 sodium 170142-29-7 98%
    ZD 9379 sodium is a competitive glycine/NMDA receptor antagonist, with an IC50 value of 75 nM (glutamate site). ZD 9379 sodium selectively antagonizes the glycine binding site (GlyB site) on the NMDA receptor, inhibiting the binding of glycine to the NMDA receptor and alleviating excitotoxicity. ZD 9379 sodium reduces the frequency of cortical spreading depression (SDs), alleviates energy depletion in the ischemic penumbra, and delays the expansion of infarction. ZD 9379 sodium reduces the infarct volume and improves neurological function in mouse models. ZD 9379 sodium can be used in studies of acute ischemic stroke, etc.
    ZD 9379 sodium
  • HY-106993A
    Cipralisant maleate 223420-20-0 99.84%
    Cipralisant (GT-2331) (maleate) is an orally active, low-toxicity, potent, selective, high affinity histamine H3 receptor full antagonist in vivo, and an agonist in vitro, with a pKi of 9.9 for histamine H3 receptor and a Ki of 0.47 nM for rat histamine H3 receptor. Cipralisant (maleate) has the potential for attention-deficit hyperactivity disorder research. Cipralisant (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Cipralisant maleate
  • HY-106993B
    Cipralisant (enantiomer) 223420-11-9
    Cipralisant (GT-2331) enantiomer is the enantiomer of Cipralisant (HY-106993), Cipralisant is an orally active, potent, selective, and high affinity histamine H3 receptor antagonist (rat Ki=0.47 nM). Cipralisant (enantiomer) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Cipralisant (enantiomer)
  • HY-107094A
    MT-7716 free base 610323-32-5 98%
    MT-7716 free base (W-212393) is a selective non-peptide nociceptin receptor (NOP) agonist and promising potential treatment drug for alcohol abuse and relapse prevention.
    MT-7716 free base
  • HY-107111A
    GSK1034702 hydrochloride 932373-86-9 98%
    GSK1034702 hydrochloride is an orally active and allosteric agonist of M1 mAChR (pEC50=8.1) that can cross the blood-brain barrier. GSK1034702 hydrochloride activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 hydrochloride can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 hydrochloride can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions).
    GSK1034702 hydrochloride
  • HY-107116S
    MAP4343-d4 98%
    MAP4343-d4 is the deuterium labeled MAP4343. MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.
    MAP4343-d4
  • HY-107125A
    AVN-322 free base 1194574-33-8 98%
    AVN-322 free base is an orally active, highly selective 5-HT6Rantagonist for central nervous system disease research.
    AVN-322 free base
  • HY-107323A
    Bentazepam hydrochloride 29462-19-9 98%
    Bentazepam (QM 6008, Thiadipone) hydrocholide is a compound with short-action anxiolytic effect. Bentazepam hydrocholide shows anticonvulsant and sedative properties. Bentazepam hydrocholide can be used for the research of depressive disorder and anxiety.
    Bentazepam hydrochloride
  • HY-107413G
    SR11237 (GMP) 146670-40-8
    SR11237 GMP is SR11237 (HY-107413) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SR11237 is a RXR activator and lipid metabolism regulator that promotes the differentiation of induced neural stem cells into dopaminergic (TH-positive) neurons. SR11237 induces transcriptional regulation of lipogenic genes and cholesterol transporters, increases glycosaminoglycan release, and elevates total cellular triglyceride levels. SR11237 promotes heterodimerization of RXR with Nurr1, thereby enhancing tyrosine hydroxylase expression and facilitating dopamine release. SR11237 produces a synergistic effect when used in combination with bFGF/EGF. SR11237 is mainly used in studies related to osteoarthritis and Parkinson's disease.
    SR11237 (GMP)
  • HY-107482A
    Picamilon sodium 62936-56-5
    Picamilon sodium is an orally active derivative of γ-aminobutyric acid that has nootropic effect. Picamilon sodium improves the epilepsy model in rats and promotes correction of functional disorders of the pancreas during Alloxan (HY-W017227)-induced diabetes mellitus in rats.
    Picamilon sodium
  • HY-107520A
    MNI-caged-L-glutamate TFA 2226362-29-2 98%
    MNI-caged-L-glutamate TFA is an inert photolabile glutamate precursor. MNI-caged-L-glutamate TFA does not modulate NMDA and AMPA receptor function in cultured neurones. MNI-caged-L-glutamate TFA can be used for research on neurotransmitters.
    MNI-caged-L-glutamate TFA
Cat. No. Product Name / Synonyms Application Reactivity